Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5805311 | 0.93 | HTT (0.45) | EGFRCHEK1KDRMAPTUBE2N | |
| SCHEMBL4169210 | 0.93 | HMGCR (0.47) | EGFRCHEK1KDRMAPTUBE2N | |
| SCHEMBL5804950 | 0.93 | KDR (0.42) | EGFRCHEK1KDRMAPTUBE2N | |
| SCHEMBL5808861 | 0.93 | HTT (0.45) | EGFRCHEK1KDRMAPTUBE2N | |
| SCHEMBL5807727 | 0.91 | HMGCR (0.46) | EGFRCHEK1KDRMAPTUBE2N | |
| SCHEMBL5804872 | 0.91 | RAB9A (0.46) | GAASMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL5808355 | 0.91 | KCNK9 (0.43) | EGFRCHEK1KDRMAPTUBE2N | |
| SCHEMBL5809279 | 0.90 | MAPT (0.49) | EGFRCHEK1KDRMAPTUBE2N | |
| SCHEMBL5806885 | 0.89 | CHEK1 (0.42) | EGFRCHEK1KDRMAPTUBE2N | |
| SCHEMBL5805004 | 0.88 | ALDH1A1 (0.46) | EGFRCHEK1KDRMAPTUBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384973-B2 | Materials and methods for treating hypercholesterolemia | ARYX THERAPEUTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080132561-A1 | Hydroxy-3-methylglutaryl/3-/ coenzyme inhibitors with high first-pass metabolism and/or short plasma half-life; to prevent Coronary Artery Disease (CAD) by lowering LDL cholesterol levels; highly predictable pharmokinetic profile; reduce systemic exposure to the active drug | ARYX THERAPEUTICS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7323490-B2 | Pyrrole compounds and uses thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| WO-2006110918-A1 | PYRROLE COMPOUNDS AND USES THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132561-A1 | Hydroxy-3-methylglutaryl/3-/ coenzyme inhibitors with high first-pass metabolism and/or short plasma half-life; to prevent Coronary Artery Disease (CAD) by lowering LDL cholesterol levels; highly predictable pharmokinetic profile; reduce systemic exposure to the active drug | HMGCR, PCSK9, PON1 | EGFR 2656/4885CHEK1 4204/4885KDR 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.